ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P ASX 200
7,044.90
(
0.42%
)
S&P ASX All Technology
2,456.00
(
1.19%
)
Brent Oil
81.525
(
0.06%
)
US Dollar vs AUD
1.50232
(
0.01%
)
Bitcoin
37,999.31
(
0.43%
)
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Evolus Inc (EOLS)

  7. Evolus Inc (EOLS) News

EOLS Evolus Inc

9.54
0.03 (0.32%)
29 Nov 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Evolus Inc EOLS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.03 0.32% 9.54 11:47:41
Open Price Low Price High Price Close Price Previous Close
9.56 9.32 9.64 9.54 9.51
more quote information »

Recent News

Date Time Source Heading
11/11/202309:16BWEvolus Reports Inducement Grants Under Nasdaq Listing Rule..
08/11/202309:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202308:24EDGAR2Form 8-K - Current report
08/11/202308:16BWEvolus Reports Record Third Quarter 2023 Financial Results..
07/11/202300:45BW“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates..
01/11/202323:45BWEvolus to Participate in November Investor Conferences
25/10/202323:45BWEvolus to Report Third Quarter 2023 Results
19/10/202307:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202307:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/10/202308:27EDGAR2Form S-8 - Securities to be offered to employees in employee..
30/9/202306:05BWEvolus Reports Inducement Grants Under Nasdaq Listing Rule..
09/9/202310:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:45BWEvolus to Participate in September Conferences
24/8/202310:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202310:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
24/8/202308:53BWEvolus Announces Inducement Grants for New Chief Marketing..
21/8/202322:45BWEvolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing..
17/8/202310:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202310:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202306:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202306:05EDGAR2Form SC 13D/A - General statement of acquisition of..
08/8/202322:45BWEvolus Unveils New Branding for Flagship Product Jeuveau® to..
03/8/202307:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202306:08EDGAR2Form 8-K - Current report
03/8/202306:05BWEvolus Reports Second Quarter 2023 Results and Provides..
27/7/202322:55EDGAR2Form 8-K - Current report
27/7/202322:45BWEvolus Raises Full-Year Revenue Guidance on Record Second..
26/7/202322:45BWEvolus to Participate in Canaccord Genuity’s 43rd Annual..
19/7/202322:45BWEvolus to Report Second Quarter 2023 Results and Provide..
29/6/202323:00BWEvolus Launches Nuceiva® (botulinum toxin type A) in Italy
22/6/202322:45BWEvolus Announces Successful Completion of Phase 2 Study..
09/6/202306:05BWEvolus Reaches 1 Million Redemptions in its Evolus Rewards™..
10/5/202306:01BWEvolus Announces Expansion into U.S. Dermal Filler Market..
06/5/202303:37BWEvolus to Report First Quarter 2023 Results and Provide..
09/3/202308:05BWEvolus Reports Fourth Quarter and Full Year 2022 Results and..
01/3/202300:45BWEvolus to Participate in the Barclays Global Healthcare..
28/2/202300:45BWEvolus Initiates Nuceiva® Launch in Germany and Austria
23/2/202300:45BWEvolus to Report Fourth Quarter and Year End 2022 Results..
11/2/202303:07BWEvolus Not Affected by Recent Korean Court Ruling
01/2/202300:45BWEvolus to Participate in the SVB Securities Global Biopharma..
29/1/202300:00BW"Extra-Strength" Formulation of Jeuveau® Demonstrates..
24/1/202301:00BWEvolus Receives Regulatory Approval for Nuceiva® in..
24/1/202300:00BWEvolus to Present Phase 2 Interim Data from Jeuveau®..
19/1/202300:45BWEvolus Announces Preliminary Unaudited Fourth Quarter and..
09/12/202200:45BWEvolus Extends Term of Credit Facility with Pharmakon..
08/12/202202:00PRNUSLeading MedTech marketplace Pipeline Medical now provides..

Your Recent History

NASDAQ
EOLS
Evolus

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com